Cell line · CVCL_1535
Papers37
1 to 20 of 37
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E2A selectively regulates TGF-β-induced apoptosis in KRAS-mutant non-small cell lung cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. | J Thorac Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. | Cell Rep | 2020 | Its Methods give the RRID and name the line | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. | Nat Commun | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1535/papers